New cancer drug enters human testing
NCT ID NCT06682780
Summary
This study is testing a new drug called LM-2417 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and see how well the body handles the drug, both alone and when combined with other cancer therapies. Researchers will also get an early look at whether the treatment helps shrink tumors or control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
FuDan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.